抗肿瘤药物处方专项点评实践的体会

Experience of Antineoplastic Prescription Special Review

目的:为提高医院抗肿瘤药物处方专项点评质量提供参考。方法:用回顾与对比法,就《北京市医疗机构处方专项点评指南(试行)》(以下简称《指南》)的工作表与自拟工作表对比分析,同时对抗肿瘤药物门诊处方点评工作中存在的问题进行讨论。结果:《指南》工作表1、表2和自拟工作表1、表2用药指标存在差异,前者是药品品种数统计指标,后者是合理用药国际调研处方指标;存在问题有药品说明书[包括同种药品不同厂家说明书不一致、药品说明书与美国国立综合癌症网络(NCCN)指南不一致、药品说明书与《新编药物学》(16版)不一致],处方前记项目设置缺失,人为分解处方。结论:专项处方点评质量的提升亟待药品说明书和指导性规范的完善,以及医院信息系统的有力支撑。

OBJECTIVE： To provide reference for the quality improvement of antineoplastic drugs prescription special review. METHODS： By review and comparison method, the worksheet of Prescription Special Review Guide in Beijing Medical Institutions （trial） （hereinafter referred to as the Guidelines） was compared with self-made one. The problems about outpatient prescription review for antineoplastic drugs were also discussed. RESULTS： The worksheet 1 and worksheet 2 of Guidelines were different from self-made worksheet 1 and worksheet 2; the former was drug type statistics index, and the latter was international research prescription indicators of rational drug use. The problems included： the package inserts of the same kinds of drugs from different manufacturers were different from one another; the package inserts were inconsistent with NCCN guidelines; the package inserts were inconsistent with 16 version of New Pharmacology; item record setting before prescribing missed; the prescription was decomposed artificially. CONCLUSIONS： The quality improvement of special prescription review requires promoting package inserts and guide specifications urgently, and needs strong HIS support.